{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T06:30:37Z","timestamp":1778221837292,"version":"3.51.4"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>There is increasing evidence to support the use of temozolomide therapy for the treatment of metastatic phaeochromocytoma\/paraganglioma (PPGL) in adults, particularly in patients with <jats:italic>SDHx<\/jats:italic> mutations. In children however, very little data is available. In this report, we present the case of a 12-year-old female with a SDHB-related metastatic paraganglioma treated with surgery followed by temozolomide therapy. The patient presented with symptoms of palpitations, sweating, flushing and hypertension and was diagnosed with a paraganglioma. The primary mass was surgically resected six weeks later after appropriate alpha- and beta-blockade. During the surgery extensive nodal disease was identified that had been masked by the larger paraganglioma. Histological review confirmed a diagnosis of a metastatic SDHB-deficient paraganglioma with nodal involvement. Post-operatively, these nodal lesions demonstrated tracer uptake on <jats:sup>18<\/jats:sup>F-FDG PET-CT. Due to poor tumour tracer uptake on <jats:sup>68<\/jats:sup>Ga-DOTATATE and <jats:sup>123<\/jats:sup>I-MIBG functional imaging studies radionuclide therapy was not undertaken as a potential therapeutic option for this patient. Due to the low tumour burden and lack of clinical symptoms, the multi-disciplinary team opted for close surveillance for the first year, during which time the patient continued to thrive and progress through puberty. 13 months after surgery, evidence of radiological and biochemical progression prompted the decision to start systemic monotherapy using temozolomide. The patient has now completed ten cycles of therapy with limited adverse effects and has benefited from a partial radiological and biochemical response.<\/jats:p>","DOI":"10.3389\/fendo.2022.1066208","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T06:13:09Z","timestamp":1667974389000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["The use of temozolomide in paediatric metastatic phaeochromocytoma\/paraganglioma: A case report and literature review"],"prefix":"10.3389","volume":"13","author":[{"given":"Calum","family":"Urquhart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ines","family":"Harper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Aloj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liz","family":"Hook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna-May","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferdia A.","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary A.","family":"McLean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Tarpey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasilis","family":"Kosmoliaptsis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Emile J.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth T.","family":"Casey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00191","article-title":"Translating in vivo metabolomic analysis of succinate dehydrogenase\u2013deficient tumors into clinical utility","volume":"2","author":"Casey","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3747\/co.v18i1.675","article-title":"The use and effectiveness of temozolomide in children with central nervous system tumours: a survey from the Canadian paediatric brain tumour consortium","volume":"18","author":"Bartels","year":"2011","journal-title":"Curr Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.08.141","article-title":"Temozolomide in malignant gliomas of childhood: A united kingdom children\u2019s cancer study group and French society for pediatric oncology intergroup study","volume":"20","author":"Lashford","year":"2002","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejim.2018.01.015","article-title":"Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: A nationwide study and systematic review","volume":"51","author":"Berends","year":"2018","journal-title":"Eur J Intern Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-3829","article-title":"Characteristics of pediatric vs adult pheochromocytomas and paragangliomas","volume":"102","author":"Pamporaki","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaa039","article-title":"Pheochromocytoma and paraganglioma in children and adolescents: Experience of the French society of pediatric oncology (SFCE)","volume":"4","author":"de Tersant","year":"2020","journal-title":"J Endocr Soc"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2022.936178","article-title":"Pediatric metastatic pheochromocytoma and Paraganglioma: Clinical presentation and diagnosis , genetics , and therapeutic approaches","volume":"13","author":"Kuo","year":"2022","journal-title":"Frontiers in Endocrinology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2830","article-title":"A current review of the etiology, diagnosis, and treatment of pediatric pheochromocytoma and paraganglioma","volume":"95","author":"Waguespack","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1806651","article-title":"Pheochromocytoma and paraganglioma","volume":"381","author":"Neumann","year":"2019","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/his.13277","article-title":"Succinate dehydrogenase (SDH)-deficient neoplasia","volume":"72","author":"Gill","year":"2018","journal-title":"Histopathology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2014.162","article-title":"Toward an improved definition of the genetic and tumor spectrum associated with SDH germ-line mutations","volume":"17","author":"Evenepoel","year":"2015","journal-title":"Genet Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4158\/EP15725.OR","article-title":"Characteristics and outcomes of metastatic SDHB and sporadic Pheochromocytoma\/Paraganglioma: an national institutes of health study","volume":"22","author":"Turkova","year":"2016","journal-title":"Endocr Pract"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14289","article-title":"A review of the tumour spectrum of germline succinate dehydrogenase gene mutations: Beyond phaeochromocytoma and paraganglioma","volume":"93","author":"MacFarlane","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-016-0084-2","article-title":"68Ga-DOTATATE and 18F-FDG PET\/CT in paraganglioma and pheochromocytoma: utility, patterns and heterogeneity","volume":"16","author":"Chang","year":"2016","journal-title":"Cancer Imaging"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.259689","article-title":"Imaging of pheochromocytoma and paraganglioma","volume":"62","author":"Carrasquillo","year":"2021","journal-title":"J Nucl Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-00816","article-title":"Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma","volume":"102","author":"Kong","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-3205","article-title":"Genotype-dependent brown adipose tissue activation in patients with pheochromocytoma and paraganglioma","volume":"101","author":"Puar","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa982","article-title":"Metastatic pheochromocytomas and abdominal paragangliomas","volume":"106","author":"Granberg","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28913","article-title":"SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma","volume":"135","author":"Hadoux","year":"2014","journal-title":"Int J Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-21-0392","article-title":"SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma","volume":"29","author":"Perez","year":"2022","journal-title":"Endocr Relat Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-006-0081-z","article-title":"Role of temozolomide in pediatric brain tumors","volume":"22","author":"Barone","year":"2006","journal-title":"Child\u2019s Nerv Syst"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.04.030","article-title":"Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)","volume":"47","author":"Patel","year":"2011","journal-title":"Eur J Cancer."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00061","article-title":"Temozolomide is a potential therapeutic tool for patients with metastatic Pheochromocytoma\/Paraganglioma\u2013case report and review of the literature","volume":"11","author":"Tong","year":"2020","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.5964","article-title":"Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity","volume":"26","author":"Hegi","year":"2008","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23812","article-title":"Treatment of malignant pheochromocytoma\/paraganglioma with cyclophosphamide, vincristine, and dacarbazine","volume":"113","author":"Huang","year":"2008","journal-title":"Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11864-020-00787-z","article-title":"Emerging treatments for Advanced\/Metastatic pheochromocytoma and paraganglioma","volume":"21","author":"Ilanchezhian","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","article-title":"Phase II study of high-dose [131I]Metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma","volume":"27","author":"Gonias","year":"2009","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26314","article-title":"Acute myeloid leukemia therapy elicits durable complete response in chemoradio-resistant metastatic paraganglioma","volume":"64","author":"Sait","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30020","article-title":"Metastatic and multiply relapsed SDH-deficient GIST and paraganglioma displays clinical response to combined poly ADP-ribose polymerase inhibition and temozolomide","author":"Singh","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/GRF.0b013e3181f96b54","article-title":"Toxicity of chemotherapy and radiation on female reproduction","volume":"53","author":"Meirow","year":"2010","journal-title":"Clin Obstet Gynecol."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2016.45","article-title":"Late endocrine effects of childhood cancer","volume":"12","author":"Rose","year":"2016","journal-title":"Nat Rev Endocrinol 2016 126"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1066208\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T06:13:11Z","timestamp":1667974391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1066208\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,9]]},"references-count":32,"alternative-id":["10.3389\/fendo.2022.1066208"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.1066208","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,9]]},"article-number":"1066208"}}